Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · P3 Health Partners Inc. (PIII)

P3 Health Partners raises 2026 adjusted EBITDA guidance midpoint to $100 million

Positive Impact 4 of 5 earnings

P3 Health Partners reported third quarter 2026 revenue of $396 million, up 15% from a year earlier, and net income of $30.8 million versus a net loss of $69.5 million in the prior-year quarter. The company raised the low end of its full-year 2026 Adjusted EBITDA guidance to $90 million, moving the midpoint to $100 million, though the quarter also benefited from payer settlements and prior-year development.

Key points

  • Q3 2026 total revenue was $396 million, up 15% from $345 million a year earlier.
  • Q3 2026 Adjusted EBITDA was $20.9 million, compared with a loss of $45.9 million in Q3 2025.
  • Full-year 2026 Adjusted EBITDA guidance is now $90 million to $110 million, up from a lower low end.
  • Q3 medical margin of $43.9 million included favorable payer settlements; excluding these items it was $35.0 million.

The filing

CompanyP3 Health Partners Inc. (PIII)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:24 PM ET
Accession number0001832511-26-000045

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 4:46 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.